Stephens & Co. analyst George Sellers reinstates Staar Surgical (NASDAQ:STAA) with a Overweight and announces $91 price target.
Revance Announces FDA Approval of DAXXIFY For Injection, A Peptide-Formulated Neuromodulator With Long-Lasting Results
Approved label includes full 36-week efficacy data from Phase 3 SAKURA clinical program, positioning DAXXIFY™ as the first and only long-acting neuromodulator that demonstrates a median duration of six months and
